Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
CYTH Stock | USD 0.66 0.06 10.00% |
Under 80 percent of all Cyclo Therapeutics' traders are aggressively thinking of buying. The analysis of the overall investor sentiment regarding Cyclo Therapeutics suggests that a large number of traders are excited. Cyclo Therapeutics' investing sentiment shows overall attitude of investors towards Cyclo Therapeutics.
Cyclo |
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclos lead clinical program Trappsol Cyclo N
Read at gurufocus.com
Cyclo Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cyclo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cyclo Therapeutics Fundamental Analysis
We analyze Cyclo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Cyclo Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cyclo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyclo Therapeutics stock to make a market-neutral strategy. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics with similar companies.
Peers
Cyclo Therapeutics Related Equities
LFCR | Lifecore Biomedical | 14.41 | ||||
TKNO | Alpha Teknova | 4.69 | ||||
IRWD | Ironwood Pharmaceuticals | 4.16 | ||||
ASRT | Assertio Therapeutics | 3.53 | ||||
AMRX | Amneal Pharmaceuticals, | 0.77 | ||||
ITCI | Intracellular | 0.62 | ||||
PAHC | Phibro Animal | 1.01 | ||||
AQST | Aquestive Therapeutics | 2.45 | ||||
PTPI | Petros Pharmaceuticals | 14.89 |
Complementary Tools for Cyclo Stock analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |